The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move that strengthens Novo Nordisk's leadership in the booming obesity drug market, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wegovy tablets (semaglutide) as the first daily oral treatment for weight management. The approval is based on the OASIS 4 trial results, which demonstrated the efficacy of the 25 mg tablets in adults with obesity or overweight conditions compared to a placebo. Novo Nordisk anticipates the pill will be available via private prescription in the UK within weeks.
Sign in to access this content
Sign InThis regulatory expansion comes amid intensifying competition with Eli Lilly’s Zepbound, as manufacturers race to diversify delivery methods to bypass supply chain bottlenecks associated with injectable pens. Per market data, Novo Nordisk (NVO) shares closed at $42.81 on June 10, 2026, amid broader healthcare sector volatility. Recent earnings reports indicate that the company's obesity care sales grew by over 40% in the previous quarter, making this UK approval a strategic catalyst for maintaining growth momentum.
Investors should watch for support levels near the recent low of $41.66 for NVO (as of June 10, 2026 close). Looking at the economic calendar, while UK-specific data like the Halifax House Price Index may influence general sentiment, the primary focus will remain on the commercial rollout speed of the pill. Traders are also monitoring upcoming central bank commentary for potential impacts on the valuations of large-cap pharmaceutical growth stocks.